Stathmin as a marker for malignancy in pheochromocytomas

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 1, 2010, Pages 27-30

  Bjorklund P ^a   Cupisti, K ^a,b   Fryknas M ^c   Isaksson, A ^c   Willenberg, H S ^b   Kerstrom G ^a   Hellman, P ^a   Westin, G ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Benign; Malignant; Microarray; Op18; Pheochromocytoma; Stathmin; STMN1

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; STATHMIN;

ADULT; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR CLONING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADRENAL MEDULLA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CHROMOSOME ABERRATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HISTOPATHOLOGY; IMMUNOHISTOLOGY; KARYOTYPE; REAL TIME POLYMERASE CHAIN REACTION;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; ADULT; AGED; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHEOCHROMOCYTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATHMIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 76749113406     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1202789     Document Type: Article

References (33)

1. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial pheochromocytoma. Lancet 2001 357 1181-1182
2. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001 69 49-54
3. Baldassare G, Belleti B, Nicoloso MS, et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005 7 51-63
4. Bender BU, Gutsche M, Glasker S, et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab. 2000 85 4568-4574
5. Benn DE, Dwight T, Richardson AL, et al. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Res. 2000 60 7048-7051
6. Bjorklund P, Akerstrom G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab. 2007 92 338-344
7. Cascon A, Ruiz-Llorente S, Rodriguez-Perales S, et al. A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes Chromosomes Cancer 2005 42 260-268
8. Curmi PA, Nogues C, Lachkar S, et al. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 2000 82 142-150
9. Dannenberg H, Speel EJ, Zhao J, et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol. 2000 157 353-359
10. Edstrom E, Mahlamaki E, Nord B, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol. 2000 156 651-659
11. Elkahloun AG, Powers JF, Nyska A, et al. Gene Expression Profiling of Rat Pheochromocytoma. Ann NY Acad Sci. 2006 1073 290-299
12. Fryknas M, Wickenberg-Bolin U, Goransson H, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol. 2006 27 211-220
13. Geli J, Nord B, Frisk T, et al. Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytoma and abdominal paragangliomas. Int J Oncol. 2005 26 1385-1391
14. Goldstein RE, ONeill Jr JA, Holcomb 3rd GW, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999 229 755-764
15. Gunawan B, Schlomm T, Schulten HJ, et al. Cytogenetic characterization of 5 pheochromocytomas. Cancer Genet. Cytogenet. 2004 154 163-166
16. Hergovich A, Lisztwan J, Barry R, et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol. 2003 5 64-70 (Pubitemid 36054331)
17. Holmfeldt P, Brannstrom K, Stenmark S, et al. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18 - >e mutation in leukemic cells. Mol Biol Cell 2006 17 2921-2930
18. Kouzu Y, Uzawa K, Koike H, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006 94 717-723
19. Lemeta S, Salmenkivi K, Pylkkanen L, et al. Frequent loss of heterozygosity at 6q in pheochromocytoma. Hum Pathol. 2006 37 749-754
20. Mannelli M, Ianni L, Cilotti A, et al. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999 141 619-624
21. Melhem RF, Strahler JR, Hailat N, et al. Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun. 1991 179 1649-1655
22. Melhem R, Hailat N, Kuick R, et al. Quantitative analysis of Op18 phosphorylation in childhood acute leukemia. Leukemia. 1997 11 1690-1695
23. Misek DE, Chang CL, Kuick R, et al. Transforming properties of a Q18 - >E mutation of the microtubule regulator Op18. Cancer Cell 2002 2 217-228
24. Neumann HP, Bausch B, MacWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 346 1459-1466
25. Neumann HP, Hoegerle S, Manz T, et al. How many pathways to pheochromocytoma? Semin Nephrol. 2002 22 89-99
26. Ohta S, Lai EW, Pang AL, et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 2005 114 139-143
27. Pawlu C, Bausch B, Reisch N, et al. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol. (Paris) 2005 66 178-185
28. Price DK, Ball JR, Bahrani-Mostafavi Z, et al. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest. 2000 18 722-730
29. Roos G, Brattsand G, Landberg G, et al. Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia. 1993 7 1538-1546
30. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J. Cell. Biochem. 2004 93 242-250
31. Takekoshi K, Nomura F, Isobe K, et al. Identification and initial characterization of stathmin by the differential display method in nerve growth factor-treated PC12 cells. Eur J Endocrinol. 1998 138 707-712
32. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002 26 551-566
33. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006 209 549-558